Kornimate/medical-research-clean huggingface dataset:
veaet for older veterans with chronic musculoskeletal pain pilot

Conditions: Musculoskeletal Pain

Summary: an uncontrolled pilot in which veterans age 60-95 years with chronic musculoskeletal (msk) pain will undergo emotional awareness and expression therapy (eaet) delivered over video teleconference (vtc; together veaet). this study aims to obtain early implementation outcomes, as well as evaluate efficacy and estimated effect sizes.

for this pilot, veaet will be provided to outpatient veterans age 60-95 years with chronic msk pain in order to obtain early implementation and clinical outcomes (i.e. acceptability, feasibility, appropriateness, fidelity, and effectiveness). each veteran will be provided a vtc capable tablet and technological support from a research coordinator as a strategy to overcome technology based obstacles and obtain feasibility data. veterans will receive one 90-minute individual session of veaet plus eight 90-minute weekly group sessions of veaet, all delivered over vtc to their homes. assessments will be performed at baseline, posttreatment, and 2-month follow-up remotely using outcomemd (los angeles, ca), a hipaa-compliant, va-approved web-based platform. the entire study will be performed without any in-person visits.

Eligibility criteria:
inclusion criteria: • eligible veterans are age 60-95 years old and have had at least 3 months of musculoskeletal pain, including the following conditions most likely to benefit from psychotherapy based on previous research: low back, neck, leg, or pelvic pain; temporomandibular joint disorders; fibromyalgia; tension headaches; or any combination of these disorders. exclusion criteria: * musculoskeletal conditions likely to respond surgical or pharmacologic treatment: hip or knee osteoarthritis, leg pain greater than back pain (to exclude radiculopathy), electromyography-confirmed "tunnel" syndrome (e.g., carpal tunnel syndrome), gout, neuralgias, migraine, and cluster headaches; * non-musculoskeletal pain conditions: autoimmune disease that typically generates pain (e.g., rheumatoid arthritis), cancer pain, sickle cell disease, burn pain, infection associated with pain, and cauda equina syndrome; * the following conditions or circumstances: severe psychiatric disorder such as schizophrenia or bipolar i disorder not controlled with medications, active suicide or violence risk, active severe alcohol or substance use disorder, substantial cognitive impairment based on chart review, previously completed eaet, currently enrolled in another psychological treatment for chronic pain, currently in pain-related litigation or applying for pain-related compensation or compensation increase (e.g., va service connection for chronic pain), unable to fluently read or converse in english, no internet access.

Keywords: chronic pain psychotherapy musculoskeletal disease video teleconference delivered therapy
permissive hypercapnia and brain development in premature infants

Conditions: Premature Birth

Summary: in the us, every year approximately 30,000 infants are born very prematurely, with birth weight less than 1000 grams. these infants usually require ventilators to help them breath normally during the first few weeks of life. although the ventilator is lifesaving, it can also injure the very fragile lungs of these infants. thus, a ventilation strategy, called permissive hypercapnia (high carbon dioxide), is widely used to prevent lung injury. importantly, there is new research showing that high carbon dioxide may cause brain injury. in our proposed research, we will use magnetic resonance imaging methods to evaluate the brain in 40 very premature infants at term-equivalent age (half of them had permissive hypercapnia ventilation, the other half did not) to see if permissive hypercapnia has adverse effect on brain development.


Eligibility criteria:
inclusion criteria: * premature infants with birth weight 401-1000 g exclusion criteria: * those with complex congenital anomalies, central nervous system malformations, chromosomal abnormalities, or hydrops fetalis
functional capacity in patients post mild covid-19

Conditions: COVID-19

Summary: patients recovered from mild coronavirus 2019 (covid-19) disease without pulmonary involvement may experience long-term physical impairment and dyspnea. the investigators aim to characterize physiologic limitations in patients who recovered from mild covid-19. methods: pulmonary function tests (pfts), 6-minute walk test (6mwt), echocardiography and cardiopulmonary exercise test (cpet) will be completed in patients recovered from mild covid-19 disease with prolonged dyspnea (subgroup "a") and compared to patients recovered from moderate/severe covid-19 (subgroup "b") and to non-covid-19 patients with unexplained dyspnea (subgroup "c").

infection with severe acute respiratory syndrome coronavirus-2 leads to severe disease requiring hospitalization in 20% of the cases. respiratory failure from severe acute respiratory syndrome coronavirus-2 infection can range from mild pneumonia and hypoxia to life threatening hypoxia secondary to severe acute respiratory distress syndrome requiring intensive care unit and mechanical ventilation in about 12-24% of the hospitalized patients. most patients are discharged with minimal or no long-term oxygen therapy while others are discharged with ongoing respiratory symptoms and long-term oxygen therapy. in the longer term, there is a significant concern that severe coronavirus disease 2019 can lead to organizing pneumonia and severe acute lung injury with evolution to widespread fibrotic changes as seen in fatal cases of coronavirus disease showing pulmonary fibrosis at autopsy. studies in severe acute respiratory syndrome survivors, another corona virus infection, showed persistent and significant impairment of exercise capacity and health status over 24 months based on pfts, 6-minute walk test and health questionnaire. infection with respiratory syndrome coronavirus-2 has been also associated with multiple direct and indirect cardiovascular complications including acute myocardial injury, myocarditis, arrhythmias, and venous thromboembolism. however, long term cardiovascular consequences from coronavirus disease 2019 are still unknown. the investigators sought to determine the pulmonary, cardiac and other physiologic limitations in patients who recovered from severe coronavirus disease 2019 with physiologic tests including pfts, echocardiography and cardio-pulmonary exercise test which is currently the most comprehensive physiologic test that can differentiate between the different limitations and add novel data regarding short and long term physiologic consequences of coronavirus disease 2019.

Eligibility criteria:
inclusion criteria: * patients recovering from covid-19 with a documented infection with severe acute respiratory syndrome coronavirus-2 and cognitive ability to sign informed consent and physical ability to participate in exercise tests. exclusion criteria: * patients with severe pulmonary, cardiac disease prior to covid-19, pregnant women, and patients with active infection or cancer.

Keywords: cardiopulmonary exercise testing covid-19 exertional dyspnea
500mg fulvestrant versus exemestane in mbc

Conditions: Breast Cancer

Summary: 500mg fulvestrant versus exemestane in mbc

500mg fulvestrant versus exemestane in metastatic breast cancer (mbc) resistant to adjuvant non-steroidal aromatase inhibitors in clinical practice- a multicenter retrospective study

Eligibility criteria:
inclusion criteria: * postmenopausal woman, age \> 18 years old * diagnosed with er/pr+，her2- metastatic breast cancer * adjuvant treatment of non-steroidal aromatase inhibitors * first line of metastatic breast cancer is 500mg fulvestrant or exemestane for at least one month, starting from 2014.01.01-2017.06.01 * available medical history exclusion criteria: * incomplete medical history

Keywords: fulvestrant exemestane
observation of initial procalcitonin and the clinical course of patients with acute respiratory tract infections

Conditions: Respiratory Tract Infections

Summary: observation of the initial procalcitonin values and the clinical course of consecutively included patients with acute respiratory tract infections at general medical practices in greater hannover.

primary endpoint: * initial procalcitonin values of patients with acute respiratory tract infections secondary endpoints: * correlation of initial procalcitonin values to classify acute respiratory tract infections * correlation of initial procalcitonin values to subjective severity of acute respiratory tract infections * correlation of initial procalcitonin values to antibiotic- prescriptions * correlation of initial procalcitonin values to frequency of admission to hospital * correlation of initial procalcitonin values to frequency of referrals (radiology, pneumology)

Eligibility criteria:
inclusion criteria: * written informed consent * all types of respiratory tract infection according to investigator´s diagnosis exclusion criteria: * pretreatment with antibiotics in the past 2 weeks * portal hypertension * major surgeries or multiple trauma which require hospitalization, in previous 4 weeks * autoimmune disease and systemic diseases (lupus erythematodes, wegener´s disease) * peritoneal dialysis * acute treated or recently operated medullary c-cell-carcinoma, sclc, carcinoid * other inflammatory diseases (e.g. urinary tract infection, pyelonephritis, pancreatitis

Keywords: primary care procalcitonin acute respiratory tract infection
pilot testing for midline measuring device

Conditions: Ventriculo-Peritoneal Shunt Infection

Summary: identifying the exact middling on the patient's head during the planning phase of surgery is crucial yet can be challenged by patient's head position and hair. the investigators have invented a device that uses anatomical landmark to quickly and gracefully identify the midline on a patient's head. the device is a u-shaped instrument equipped with a laser pointer at the midline. the instrument also has smooth spheres that can be positioned over the patients' ears bilaterally. the midline laser pointer will identify the midline on the patients' head. this measurement procedure is typically done after the patient is placed under anesthesia. the standard way of determining the midline on the skull is simply by surgeon's vision without any measurements. this new technique will be contrasted against the standard way. the device was invented by investigators in neurosurgery (led by dr. matthew howard iii). this is not patented it at this time. there is no company involved in manufacturing (assembly was completed with the help of the hospital's machine shop).


Eligibility criteria:
inclusion criteria: * patients with normal pressure hydrocephalus who are scheduled to undergo a ventriculoperitoneal shunt surgery exclusion criteria: * patients who are not able to consent
intrathecal fentanyle versus dexamethasone in gynacological laparoscopic surgeries

Conditions: Intraoperativ Pain

Summary: laparoscopy was first introduced to the medical field of in the middle of the last century. it revolutionized the surgical interventions; it reduced the total medical expenditures and hastened postoperative recovery . general anaesthesia (ga) was considered the only anesthetic technique suitable for laparoscopic interventions, and several myths and facts prevented regional anaesthesia (ra) implementation. respiratory and cardiovascular impairment were the main aspects of concern which are thought to be best controlled by ga


Eligibility criteria:
inclusion criteria: * asa i, ii * elective gynacological laparoscopic surgery exclusion criteria: * patient refusal * chronic kidney and hepatic diseases
a single-arm phase ii study of alemtuzumab in combination with high-dose methylprednisolone in cll patients with p53 deletion

Conditions: Chronic Lymphocytic Leukaemia

Summary: this is a phase ii open label study for patients with p53-deleted cll who require treatment. both untreated and previously treated patients are eligible for study entry. the trial consists of giving continuous alemtuzumab and cyclical high-dose methyl-prednisone.alentuzumab is given intravenously during the first 4 weeks of treatment to ensure that adequate serum levels are achieved quickly. the drug will be administered daily during the first week, commencing at a dose of 3mg, and increasing to 10mg and then up to the target dose of 30mg as tolerated.thereafter alemtuzumab will be given at a dose 30mg thrice weekly. from week 5, alemtuzumab will be given at the same dose but by the subcutaneous route of administration. methlyprednisolone will be given for 5 consecutive days at a daily dose of 1.0g/m2, starting on day 1 and repeating the cycle every 28 days. treatment will be given for 16 weeks (i.e 4 cycles of methylprednisolone). treatment will be discontinued if there is no response after 8 weeks, or if toxicity becomes unacceptable.


Eligibility criteria:
inclusion criteria: * at least 18 years old * written informed consent * confirmed diagnosis of cll or sll (small mature lymphocytes n blood, bone marrow or lymph nose expressing cd19, cd5, cd23, weakk cd79b, and weak clonally restricted immunoglobin light chain) * p53 deletion by fish in at least 20% of leukamia cells * treatment is indicated (binet stage b or c, or stage a with a lyphocyte doubling time of less than 6 months, or disease-related symptoms or complications irrespective of clinical stage) * who performance status 0, 1 or 2 * both untreated and previously treated patients are eligible for study exclusion criteria: - patients must have none of the following: active infection known hiv infection past history of anaphylaxis following exposure to rat or mouse cdr-grafted humanised monoclonal antibodies less than 3 weeks since prior chemotherapy use of prior investigational agents within 6 weeks pregnancy or lactation uncontrolled diabetes mellitus uncontrolled hypertension active peptic ulcer disease other severe concurrent diseases or mental disorders serum urea or creatinine more than twice the upper limit of normal (unless due to uretic obstruction or renal infiltration by cll/sll) serum bilirubin more than twice the upper limit of normal (unless due to haemlysis or liver infiltration with cll/sll) persisting severe cytopenias due to previous therapy rather than disease (neutrophils \<0.5 x 109/l or platelets \<50 x 10/l)
effect of strontium-90 brachytherapy combined with hyperthermia in the treatment of keloid

Conditions: Keloid

Summary: keloid patients were randomized into the experimental and control groups. experimental group: strontium-90 (sr-90) brachytherapy followed by hyperthermia. control group: sr-90 brachytherapy alone .

sr-90 brachytherapy: 6-7 gy each time, twice a week for 3 weeks; hyperthermia: using a heater, 44℃ for 15 min

Eligibility criteria:
inclusion criteria: * the patient was clinically diagnosed with keloid, and the keloid area was clean without rupture and exudation； * body surface keloid thickness: 2\~5mm, diameter ≥10mm. exclusion criteria: * women who plan to become pregnant within 3 months or are pregnant or breastfeeding; * patients with cicatricial constitution; * abnormal coagulation function; * patients who have received an adequate dose or course of radiation therapy; * people with previous immune system diseases, diabetes and other metabolic diseases.
a clinical study to evaluate the remote monitoring of myopia patients with the eyeque insight

Conditions: Myopia

Summary: the objective of this study is to determine whether the remote monitoring of myopia patients with the eyeque insight (visual acuity test) can replace regularly scheduled follow-up visits.

a prospective exploratory study to determine whether the remote monitoring of myopia patients with the eyeque insight (visual acuity test) can replace regularly scheduled follow-up visits.

Eligibility criteria:
inclusion criteria: 1. male or female 2. ages =\>7 y.o. 3. subjects that are minors (\<18 years old) must have a parent or legal guardian. 4. binocular vision 5. willing and able to give informed consent and follow all study procedures and requirements 6. fluent in english 7. be treated for myopia with ortho-k, day contacts, or night contacts exclusion criteria: 1. has been diagnosed within 4 weeks, or currently has signs or symptoms, of covid-19. 2. has traveled outside the country within the last 4 weeks 3. medications: a. taking medications that may affect ability to follow instructions. 4. eye disease: a. subjects with eye disease deemed by the investigator to be inappropriate for the study such as an active eye infection, keratoconus, etc. 5. subjects that: 1. lack physical dexterity to properly operate the eyeque app on the smartphone 2. lack the ability to follow instruction 3. lack binocular vision 4. lack the ability to maintain both eyes open 5. had eye surgery within the last 12 months (including lasik)

Keywords: myopia ortho-k vision
study to evaluate the clinical impact of a laparoscopic radical prostatectomy simulator

Conditions: Prostatic Neoplasms; Cancer of Prostate; Prostate Cancer; Prostate Neoplasms

Summary: to evaluate the clinical impact of an online video simulator during the learning period of laparoscopic radical prostatectomy.

objectives: to compare two different approaches in learning laparoscopic radical prostatectomy , with or without using an online video simulator design : prospective randomized multicentric study methods: 20 surgeons considered as naive concerning their experience in laparoscopic radical prostatectomy will be randomized into two groups :1 group will use the online video simulator, 1 group will use usual learning methods except the online video simulator. all procedures will be recorded from the beginning till the end.a video review will be preformed concerning all the videos in order to identify the total operative time and time to perform each one of the operative steps of the procedure.clinical , biological and histological data will be collected in order to compare the two arms.

Eligibility criteria:
inclusion criteria: * surgeon beginning his clinical experience in laparoscopic radical prostatectomy and having performed less then 30 procedures before being enrolled in the study * surgeon who intends to begin laparoscopic radical prostatectomy clinical practice * surgeons who usually perform enough cases to enroll at least 10 patients during the study inclusion time exclusion criteria: * surgeon who does not have access to high speed internet (\>1024 ko/s) * surgeons who do not intend to begin laparoscopic radical prostatectomy in his clinical practice

Keywords: laparoscopy prostate cancer learning simulation simulator
study in low risk gastrointestinal stromal tumor (gists)

Conditions: GIST

Summary: this is a multi-institutional retrospective study in order to identify the most relevant and advisable features of follow-up, and to explore its impact on principal clinical outcomes. moreover, a dedicated effort will be pursued to identify the peculiar characteristics (if any) of patients that experienced recurrence of the disease. the study will collect data about patients affected by primary gist at very-low and low risk of recurrence/progression, referred to participating institutions between january 2000 and february 2020

in the field of soft tissue sarcomas, gastrointestinal stromal tumors (gist) represents a really peculiar neoplasm for its biological and clinical properties. surgery (if feasible) is the main therapeutic approach for all the patients with localized disease, while a pharmacological adjuvant treatment is reserved to those with a relevant risk of recurrence/progression. after tumor removal, clinical and radiological follow-up is of central importance to early intercept recurrence and to evaluate the most correct subsequent therapeutic approach. in particular, for the group of patients with gist at very-low and low risk of recurrence/progression, the evidences to support a specific follow-up program and its features are poor. on the basis of the aforementioned considerations, we propose a multi-institutional retrospective study in order to identify the most relevant and advisable features of follow-up, and to explore its impact on principal clinical outcomes. moreover, a dedicated effort will be pursued to identify the peculiar characteristics (if any) of patients that experienced recurrence of the disease. the study will collect data about patients affected by primary gist at very-low and low risk of recurrence/progression, referred to participating institutions between january 2000 and february 2020

Eligibility criteria:
inclusion criteria: * \>18 years at diagnosis * primary gist removed by surgery or endoscopic procedures * availability of medical data needed for the study * very-low and low risk gist defined as: * largest size of \< 3 cm (for all sites of origin) * gastric gist with ≤ 5/50 high power fields (hpf) mitoses and ≤ 10 cm in the largest size * gastric gist with \> 5/50 hpf mitoses and ≤ 5 cm in the largest size * intestinal gist with ≤ 5/50 hpf mitoses and ≤ 5 cm in the largest size exclusion criteria: * metastases at diagnosis. * previous treatment with imatinib

Keywords: gist gastro intestinal stromal tumor
effects of essence of chicken on physical fatigue, working memory and attention

Conditions: Healthy Subjects; Fatigue

Summary: in southeast asia, essence of chicken, a chicken-meat-extract, is a popular beverage and is consumed as a traditional remedy for several ailments, including the use as a nutritional supplement for sickness, enhancement of mental efficiency, and recovery from mental fatigue. while the elderly use it as a nutritional supplement, students use it for relief from anxiety during exam times. the present study is conducted in order to assess the effects of bec on various physical and mental parameters including physical fatigue, working memory and attention, mood and stress, in comparison to placebo.


Eligibility criteria:
inclusion criteria: * normal bmi * not continuously taken essence of chicken for the last 3 months * physical and psychological fatigue inclusion criteria/test/cutoff using cfq (where individuals' cfq scores 4 or above) exclusion criteria: * suffering from chronic or malignant diseases e.g. cancer, heart, liver, renal or other metabolic diseases. * any psychiatric or neurological disease * pregnant and lactating women * subjects participated in any investigational drug trial within 4 weeks before screening * consumption of food supplement in the previous 2 weeks * professional athletes * subjects with recent lifestyle changes in the past 4 weeks * history of allergy to chicken meat and seafood